Design and selection of peptides to block the SARS-CoV-2 receptor binding domain by molecular docking

Design and selection of peptides to block the SARS-CoV-2 receptor binding domain by molecular docking

The novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is currently one of the most contagious viruses in existence and the cause of the worst pandemic in this century, COVID-19. SARS-CoV-2 infection begins with the recognition of the cellular receptor angiotensin converting enzyme-2...

Full description

Bibliographic Details
Main Authors:	Kendra Ramirez-Acosta, Ivan A. Rosales-Fuerte, J. Eduardo Perez-Sanchez, Alfredo Nuñez-Rivera, Josue Juarez, Ruben D. Cadena-Nava
Format:	Article
Language:	English
Published:	Beilstein-Institut 2022-07-01
Series:	Beilstein Journal of Nanotechnology
Subjects:	angiotensin converting enzyme-2 (ace2) antiviral peptides hydrogen bonds molecular docking sars-cov-2 rbd
Online Access:	https://doi.org/10.3762/bjnano.13.62

Similar Items

Molecular docking study and mapping the binding site of some antiviral nanobodies against receptor binding domain (RBD) of SARS-COV 2
by: zahra pahlavan, et al.
Published: (2021-06-01)

Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein
by: Loai M. Saadah, et al.
Published: (2020-11-01)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
by: Arun Bahadur Gurung, et al.
Published: (2021-02-01)

Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
by: Harry Ridgway, et al.
Published: (2022-01-01)

Thymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epithelia
by: Yu-Hang Zhang, et al.
Published: (2022-02-01)

The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19
by: Francesca Silvagno, et al.
Published: (2020-07-01)

Exploring the Interaction between Vancomycin/Teicoplanin and Receptor Binding Domain (RBD) of SARS-CoV-2
by: Wen-Tao Tao, et al.
Published: (2021-01-01)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
by: Carlos P. Vio, et al.
Published: (2020-06-01)

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein
by: Lingbing Zhang, et al.
Published: (2022-06-01)

Severe food restriction activates the central renin angiotensin system
by: Aline Maria Arlindo De Souza, et al.
Published: (2020-01-01)

Exacerbation of COVID 19 in Hypertensive Patients ( A review)
by: Noor Hatef Naser, et al.
Published: (2021-12-01)

Circulating Soluble ACE2 Plays an Independent Role to Protect against Vascular Damage in Diabetic Mice
by: Chris Tikellis, et al.
Published: (2022-05-01)

Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike
by: Amrita Banerjee, et al.
Published: (2022-02-01)

In-silico study for the identification of potential destabilizers between the spike protein of SARS-CoV-2 and human ACE-2
by: Jeffry Medina-Barandica, et al.
Published: (2023-01-01)

Xeno-Nucleic Acid (XNA) 2’-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding
by: Irani Alves Ferreira-Bravo, et al.
Published: (2021-10-01)

Virtual Screening in Search for a Chemical Probe for Angiotensin-Converting Enzyme 2 (ACE2)
by: Iryna O. Kravets, et al.
Published: (2021-12-01)

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
by: Mandy Schwarze, et al.
Published: (2022-06-01)

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor
by: Tümay Capraz, et al.
Published: (2021-12-01)

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19
by: Artemio García-Escobar, et al.
Published: (2022-01-01)

Design of new captopril mimics as promising ACE inhibitors: ADME, pharmacophore, molecular docking and dynamics simulation with MM-PBSA and PCA calculations
by: Amany Belal, et al.
Published: (2023-12-01)

Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
by: Sonia Tamanna, et al.
Published: (2020-09-01)

Corrigendum: Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
by: Sonia Tamanna, et al.
Published: (2021-05-01)

Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2
by: Ting Wang, et al.
Published: (2022-09-01)

Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
by: Karim Bendjelid
Published: (2020-07-01)

Lactoferrin Inhibition of the Complex Formation between ACE2 Receptor and SARS CoV-2 Recognition Binding Domain
by: Roberta Piacentini, et al.
Published: (2022-05-01)

Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq
by: Ali A. Dawood, et al.
Published: (2022-07-01)

Evaluating the Spike–hACE2 interactions in the wild type and variants of concern of SARS -CoV-2 at different temperatures
by: Nabanita Mandal, et al.
Published: (2024-01-01)

Revealing the Sequence Characteristics and Molecular Mechanisms of ACE Inhibitory Peptides by Comprehensive Characterization of 160,000 Tetrapeptides
by: Mingzhe Ma, et al.
Published: (2023-04-01)

Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
by: Cosimo Cianfarini, et al.
Published: (2024-01-01)

The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains
by: Rongrong Chen, et al.
Published: (2021-01-01)

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
by: Jeroen Pollet, et al.
Published: (2021-08-01)

COVID-19: Gender and Outcomes
by: Alfonso Ilardi
Published: (2022-04-01)

Purification and Characterization of Porcine Angiotensin Converting Enzyme 2
by: Weiwei LIU, et al.
Published: (2022-09-01)

Studying the Effect of Glycosylation towards SARS-CoV-2 Spike RBD and ACE2 Interaction by Native Mass Spectrometry
by: LUO Yu-xiang;HUANG Jing;LI Hui-lin
Published: (2022-11-01)

Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries
by: Alon Ben David, et al.
Published: (2021-05-01)

Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression
by: Khushwant S. Bhullar, et al.
Published: (2022-09-01)

Aspects of the physiochemical properties of SARS-CoV-2 to prevent S-protein receptor binding using Arabic gum
by: Ghobashy Mohamed Mohamady, et al.
Published: (2022-02-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
by: Ming-Feng He, et al.
Published: (2022-10-01)

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19
by: Thi Nhu Mai Tran, et al.
Published: (2021-12-01)

Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
by: Ramesh K. Goyal, Jaseela Majeed, Rajiv Tonk, Mahaveer Dhobi, Bhoomika Patel, Kalicharan Sharma, Subbu Apparsundaram
Published: (2020-09-01)